MX2021006464A - Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. - Google Patents
Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo.Info
- Publication number
- MX2021006464A MX2021006464A MX2021006464A MX2021006464A MX2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A
- Authority
- MX
- Mexico
- Prior art keywords
- meisoindigo
- polymorphic form
- inflammatory
- modified formulation
- methylisoindigo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0025—Crystal modifications; Special X-ray patterns
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0096—Purification; Precipitation; Filtration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776965P | 2018-12-07 | 2018-12-07 | |
| PCT/US2019/062704 WO2020117487A1 (en) | 2018-12-07 | 2019-11-21 | Polymorphic form of meisoindigo and modified formulation of meisoindigo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006464A true MX2021006464A (es) | 2021-09-28 |
Family
ID=70974812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006464A MX2021006464A (es) | 2018-12-07 | 2019-11-21 | Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20220009889A1 (https=) |
| EP (1) | EP3891141A4 (https=) |
| JP (2) | JP2022511554A (https=) |
| KR (1) | KR20210102335A (https=) |
| CN (2) | CN118515598A (https=) |
| CA (1) | CA3121726A1 (https=) |
| IL (1) | IL283703A (https=) |
| MX (1) | MX2021006464A (https=) |
| WO (1) | WO2020117487A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7851300B2 (ja) | 2021-04-21 | 2026-04-24 | 住友化学株式会社 | 縮合複素環化合物を用いる衛生害虫の防除方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| CA2469649C (en) * | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| CA2868302A1 (en) * | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| PT106237B (pt) * | 2012-03-30 | 2015-03-19 | Hovione Farmaci Ncia S A | Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas |
| CN106176720A (zh) * | 2016-08-17 | 2016-12-07 | 武汉大学 | 甲异靛在制备抗炎药物中的应用 |
-
2019
- 2019-11-21 JP JP2021532308A patent/JP2022511554A/ja active Pending
- 2019-11-21 US US17/298,528 patent/US20220009889A1/en not_active Abandoned
- 2019-11-21 CN CN202410495669.6A patent/CN118515598A/zh active Pending
- 2019-11-21 MX MX2021006464A patent/MX2021006464A/es unknown
- 2019-11-21 EP EP19892926.7A patent/EP3891141A4/en active Pending
- 2019-11-21 CA CA3121726A patent/CA3121726A1/en active Pending
- 2019-11-21 KR KR1020217021317A patent/KR20210102335A/ko not_active Ceased
- 2019-11-21 CN CN201980090936.9A patent/CN113365990A/zh active Pending
- 2019-11-21 WO PCT/US2019/062704 patent/WO2020117487A1/en not_active Ceased
-
2021
- 2021-06-03 IL IL283703A patent/IL283703A/en unknown
-
2024
- 2024-08-22 JP JP2024141101A patent/JP2024170448A/ja active Pending
- 2024-11-21 US US18/955,955 patent/US20250084035A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250084035A1 (en) | 2025-03-13 |
| JP2024170448A (ja) | 2024-12-10 |
| IL283703A (en) | 2021-07-29 |
| EP3891141A1 (en) | 2021-10-13 |
| CA3121726A1 (en) | 2020-06-11 |
| US20220009889A1 (en) | 2022-01-13 |
| CN113365990A (zh) | 2021-09-07 |
| KR20210102335A (ko) | 2021-08-19 |
| WO2020117487A1 (en) | 2020-06-11 |
| EP3891141A4 (en) | 2022-10-12 |
| JP2022511554A (ja) | 2022-01-31 |
| CN118515598A (zh) | 2024-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550341A1 (en) | Niraparib formulations | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| AU2016354007A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| MX2020008017A (es) | Formulaciones de vidrio y usos de las mismas. | |
| CO2022008606A2 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| EP4596543A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| EP4252755A3 (en) | Therapeutic compounds | |
| PH12021553056A1 (en) | Modified release formulations and uses thereof | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| WO2019240699A3 (en) | Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| PH12018500469A1 (en) | Sulfonamide compounds as voltage-gated sodium channel modulators | |
| MX2021006464A (es) | Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. | |
| CO2025007025A2 (es) | Formulaciones orales compactables de ibutamoren | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| WO2020190900A8 (en) | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof | |
| MX2020005310A (es) | Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo. | |
| JOP20230099A1 (ar) | تركيبات صيدلية |